Clinical trial
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT04419558 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Kyntra Bio
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- September 30, 2020
- Completion date
- September 4, 2023
- Enrollment
- 372 (actual)
- Sites
- 157
Conditions
As the registry lists them; a condition with its own page is linked.